[1] Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy[J]. J Am Coll Cardiol, 2003, 41(9):1633-1652.
[2] 张海燕,方焕荣,杨协清,等. 血浆蛋白C基因多态性与华法林剂量相关性的研究[J]. 中国药学杂志, 2012, 47(21):1741-1745.
[3] Wadelius M, Chen LY, Lindh JD, et al. The largest prospective warfarin-treated cohort supports genetic forecasting[J]. Blood, 2009, 113(4):784-792.
[4] Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy[J]. Pharmacogenetics, 1995, 5(6):389-392.
[5] Avery PJ, Jorgensen A, Hamberg AK, et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy[J]. Clin Pharmacol Ther, 2011, 90(5):701-706.
[6] Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2[J]. Nature, 2004, 427(6974):537-541.
[7] D′Andrea G, D′Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin[J]. Blood, 2005, 105(2):645-649.
[8] Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose[J]. Blood, 2008, 112(4):1022-1027.
[9] International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data[J]. N Engl J Med, 2009, 360(8):753-764.
[10] Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups[J]. Blood, 2010, 115(18):3827-3834.
[11] Scott SA, Khasawneh R, Peter I, et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups[J]. Pharmacogenomics, 2010, 11(6):781-791.
[12] Burmester JK, Berg RL, Yale SH, et al. A randomized controlled trial of genotype-based Coumadin initiation[J]. Genet Med, 2011, 13(6): 509-518. |
